<DOC>
	<DOC>NCT01875718</DOC>
	<brief_summary>The study is a phase 1/2 study in two parts. In part 1, the primary objective is to assess the pharmacokinetics of UC1010 when administered subcutaneously as a single dose to healthy women. The safety and tolerability of UC1010 is also evaluated in study part 1. In part 2, the primary objective is to assess the pharmacodynamic effect of UC1010 on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD) when given during the luteal phase of the menstrual cycle. The pharmacodynamic effect is evaluated through the patients' daily ratings of premenstrual symptoms. In both study parts, two active treatment groups are compared to one placebo group.</brief_summary>
	<brief_title>A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)</brief_title>
	<detailed_description />
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<criteria>Part 1 Essentially healthy Part 2 Have PMDD according to DSMIV verified in two menstrual cycles steroid hormonal treatment during the previous three months treatment with psychopharmaceuticals or other treatment for PMS history of or a significant medical condition ongoing be pregnant or plan a pregnancy within the study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>